Intranasal Galanin (1–15) modulates alcohol self-administration and depressive-like behavior in rats and shows a favorable safety profile
In conclusion, intranasal administration of GAL (1-15) represents a promising candidate for clinical trials due to its favorable safety profile and therapeutic potential. Its use appears particularly suitable as a standalone treatment for alcohol use disorder and, when combined with SSRIs, as a potential therapy for depressive disorders.
Authors
- Juan Pedro Pineda-Gómez
- Zaida Dı́az-Cabiale (ORCID: https://orcid.org/0000-0003-4613-9430)
- Noelia Cantero-García (ORCID: https://orcid.org/0000-0003-3233-7532)
- María C. Ramos (ORCID: https://orcid.org/0000-0002-3674-615X)
- Antonio Flores‐Burgess (ORCID: https://orcid.org/0000-0001-9155-5674)
- Carmelo Millón (ORCID: https://orcid.org/0000-0001-7580-5506)
- Caridad Díaz (ORCID: https://orcid.org/0000-0003-1240-0143)
- Marta Flores-Gómez
Institutions
- Fundación Medina (ES)
- Instituto de Investigación Biomédica de Málaga (ES)
- Universidad de Málaga (ES)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2025-11-26
- DOI
- https://doi.org/10.3389/fphar.2025.1719440
- Citations
- 1
- Primary Topic
- Neuropeptides and Animal Physiology
- Type
- article
- Field-Weighted Citation Impact
- 0.91
Funders
- Universidad de Málaga
- Ministerio de Ciencia e Innovación
- Plan Nacional sobre Drogas
- Agencia Estatal de Investigación